CYCLE-AD: Randomized Controlled Trial to Assess the Efficacy of Indoor Cycling in Slowing Disease Progression in Healthy Older Persons at Genetic Risk for Alzheimer's Disease

PROJECT SUMMARY/ABSTRACT The CYCLE-AD (Cycling to Cease or Limit the Effects of Alzheimer’s Disease) is a randomized controlled trial (RCT) that was funded on January 15, 2021, for 5-years (end date: December 31, 2025). The overall goal of CYCLE-AD is to assess the efficacy of home-based cycling exercise intervention in slowing disease

progression in 150 healthy older persons at genetic risk for Alzheimer’s Disease. The original grant proposal was designed to recruit all participants from the metropolitan Cleveland area. We began recruitment in October 2021 intending to complete enrollment by the end of April 2024. Midway through the recruitment process, it

was realized our recruitment goal would not be met if recruitment was restricted to the metro Cleveland area. We decided to conduct a nationwide search for participants meeting the inclusion criteria. Nationwide recruitment has been successful and will result in enrollment completion by July 2024. The original budget,

however, did not include the additional travel costs associated with a nationwide search. In this proposal, we are requesting supplemental funding to cover the travel costs associated with the nationwide recruitment. The specific aims, research design, and methods of the current parent project, CYCLE-AD, have

not changed.